I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal..:
Cho, Byoung Chul
;
Yoh, Kiyotaka
;
Perets, Ruth
...
Lung Cancer, Vol.159, pp.162-170. , 2021
Link:
https://hdl.handle.net/10371/179099
RT Journal T1
Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer
UL https://suche.suub.uni-bremen.de/peid=base-ftseoulnuniv:oai:s-space.snu.ac.kr:10371_179099&Exemplar=1&LAN=DE A1 Cho, Byoung Chul A1 Yoh, Kiyotaka A1 Perets, Ruth A1 Nagrial, Adnan A1 Spigel, David R A1 Gutierrez, Martin A1 Kim, Dong-Wan A1 Kotasek, Dusan A1 Rasco, Drew A1 Niu, Jiaxin A1 Satouchi, Miyako A1 Ahn, Myung-Ju A1 Lee, Dae Ho A1 Maurice-Dror, Corinne A1 Siddiqi, Shabana A1 Ren, Yixin A1 Altura, Rachel A A1 Bar, Jair PB Elsevier BV YR 2021 K1 NIVOLUMAB PLUS IPILIMUMAB K1 OPEN-LABEL K1 1ST-LINE TREATMENT K1 TREMELIMUMAB K1 MULTICENTER K1 DURVALUMAB K1 BLOCKADE K1 MK-1308 K1 Lung neoplasms K1 CTLA-4 antigen K1 Programmed cell death 1 receptor K1 Drug therapy K1 combination K1 Immunotherapy JF Lung Cancer, Vol.159, pp.162-170 LK http://dx.doi.org/https://hdl.handle.net/10371/179099 DO https://hdl.handle.net/10371/179099 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)